EVO301 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis (AD)
Conditions
Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
Trial Timeline
Feb 13, 2025 → Nov 17, 2025
NCT ID
NCT06723405About EVO301 + Placebo
EVO301 + Placebo is a phase 2 stage product being developed by Evommune for Atopic Dermatitis (AD). The current trial status is completed. This product is registered under clinical trial identifier NCT06723405. Target conditions include Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06723405 | Phase 2 | Completed |
Competing Products
20 competing products in Atopic Dermatitis (AD)